COMMUNIQUÉS West-GlobeNewswire

Digbi Health Unifies Metabolic, Inflammatory and Hormonal Care on One Precision Biology Telehealth Platform
02/10/2026
Employers can now deliver GLP-1 and hormone replacement therapy through a unified care team, without layering on another standalone point solution MOUNTAIN VIEW, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Digbi Health [...]
The Ensign Group Adds New Operations in Colorado
02/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Adds Operations in Washington
02/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Announces Expansion Into Florida
02/10/2026
SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review
02/10/2026
LOR is now under regulatory review in both the United Kingdom and the European Union SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a late-stage biopharmaceutical company [...]
Guidepoint Qsight Reports Male Neurotoxin Spending Exceeds $500 Per Visit for the First Time
02/10/2026
New York, USA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Males Spend Also Outweighs Women’s Qsight patient transaction data shows male neurotoxin average spend per transaction in Q3-to-date at $529, the highest Qsight has ever [...]
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
02/10/2026
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational [...]
Addex Therapeutics Announces Executive Management Changes
02/10/2026
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex [...]
Ending MS Is Within Reach: National MS Society Raises a Record-Breaking $12 Million to Launch the Campaign to End MS
02/10/2026
Nearly 500 guests gathered at Cipriani 42nd Street for the Campaign to End MS Gala, emceed by Ginger Zee and honoring David Osmond and his family, as the Society kicked off its five-year, $1 billion campaign NEW YORK, [...]
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
02/10/2026
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time [...]
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
02/10/2026
TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting [...]
Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility
02/10/2026
End-to-end continuum of care, powered by medical exoskeletons, an expanded global clinical network, and trailblazing R&D capabilities, expands options for upright mobility, from rehabilitation to everyday life NEW [...]
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
01/10/2026
ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2026
NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
01/10/2026
Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan [...]
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
01/10/2026
FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
01/10/2026
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
NANOBIOTIX annonce la nomination d’Arnd Christ au poste de directeur financier
01/10/2026
PARIS et CAMBRIDGE, Mass., 01 oct. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]

Pages